Viridian Therapeutics, Inc. logo

Viridian Therapeutics, Inc.

NASDAQ:VRDN

Overview | Financials
Company Name Viridian Therapeutics, Inc.
Symbol VRDN
Currency USD
Price 19.03
Market Cap 1,507,417,681
Dividend Yield 0%
52-week-range 11.4 - 27.2
Industry Biotechnology
Sector Healthcare
CEO Mr. Scott D. Myers M.B.A.
Website https://www.viridiantherapeutics.com

An error occurred while fetching data.

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003,

Related Stocks

Nyxoah S.A. logo

Nyxoah S.A.

NYXH

8.01 USD

MeiraGTx Holdings plc logo

MeiraGTx Holdings plc

MGTX

6.15 USD

Science 37 Holdings, Inc. logo

Science 37 Holdings, Inc.

SNCE

5.75 USD

Inotiv, Inc. logo

Inotiv, Inc.

NOTV

4.08 USD

RxSight, Inc. logo

RxSight, Inc.

RXST

33.66 USD

Incannex Healthcare Limited logo

Incannex Healthcare Limited

IXHL

0.84 USD

Repare Therapeutics Inc. logo

Repare Therapeutics Inc.

RPTX

1.32 USD

Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc.

GLUE

6.93 USD

OrganiGram Holdings Inc. logo

OrganiGram Holdings Inc.

OGI

1.56 USD

Financials

Numbers are in millions USD

Numbers are in millions USD